Loading…
← CockpitCompetitor Analysis › 603207.SS Shanghai Xiao Fang Pharmaceutical Co., Ltd. Class AOpen in the cockpit ↗

Shanghai Xiao Fang Pharmaceutical Co., Ltd. Class A603207.SSCompetitor analysis, valuation and peers

China · CNY·Health Care›Pharmaceuticals: Major
Momentum strong 65
Mkt cap
$503M
US dollars, full cap
$/day
$4.12M
20-day average traded
Fwd P/E
n/m
no positive forecast
ROIC−WACC
+34.7 pp
WACC 5.0%
Hurdle
-13 pp
Req g minus delivered
Close · CNYCN¥21.04
1D-2.5%
1W-6.7%
1M-6.7%
3M-13.1%
6M-17.3%
YTD-26.5%
1Y-35.1%
ATR %2.7%
52w lowhigh35.8% off high

What Shanghai Xiao Fang Pharmaceutical does

Employees: 529

Shanghai Xiao Fang Pharmaceutical at a glance

Size Shanghai Xiao Fang Pharmaceutical (603207.SS) is a China Health Care company (Pharmaceuticals: Major) with a market value of $503M, the 3685th largest of 4,790 China companies the cockpit tracks. Shares closed at CN¥21.04 on 18 Nov 2026.

Performance Over six months the shares fell 17.3%, against -19.6% for the median peer and -20.0% for the China market (cap-weighted) — 10th highest of 21 in its peer set.

Growth Revenue grew 9.8% over the last twelve months (peer median +9.4%); the operating margin is 39.4% (peer median 6.8%).

Valuation It trades at 4.8× enterprise value to sales against a peer median of 3.7× (8th most expensive of 20).

Price implies For today's price to make sense, revenue must grow about -5% a year for seven years (Req g). Recent delivered growth is +8%, so the hurdle is -13 pp: the price already allows for a slowdown.

Capital Return on invested capital runs 34.7 points above its cost of capital (5.0% WACC).

Relative performance

809010011021 May 202621 Aug 202618 Nov 2026603207.SS 83Peer median 82
Six months, rebased to 100: Shanghai Xiao Fang Pharmaceutical against the median of its 20 peers (local-currency closes).

Shanghai Xiao Fang Pharmaceutical financials

Reported figures in CNY; fiscal year ends 2025-12-31. TTM = trailing twelve months.
TTMFY2025FY2024FY2023FY2022
RevenueCN¥554MCN¥521MCN¥471MCN¥472MCN¥457M
Revenue growth—+10%0%+3%—
Gross profitCN¥335MCN¥337MCN¥307MCN¥308MCN¥268M
EBITDAn/aCN¥241MCN¥237MCN¥233MCN¥206M
Net incomeCN¥193MCN¥207MCN¥205MCN¥204MCN¥175M
Free cash flowCN¥131MCN¥111MCN¥128MCN¥122MCN¥78.8M
Capital expenditureCN¥71.7MCN¥54.2MCN¥83.9MCN¥80.2MCN¥61.6M
Total debtCN¥5.55MCN¥9.65MCN¥2.32MCN¥442,274CN¥882,770

Quarterly statements and history in the cockpit →

Shanghai Xiao Fang Pharmaceutical competitor charts

The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.

Performance: 6-month against 1-month return

0%+50%+100%0%+20%GUJTHEMGYREINDP600222EGTXTKNO600513003090AARTIDRUGS6036761666300485301277RGNXHNSA600624603207.SS6-month return →1-month return →
Up and to the right = strong over both horizons. Shanghai Xiao Fang Pharmaceutical is the large dot.

Fundamentals: revenue growth against valuation

-20%0%+20%+40%+60%0×25×50×75×GUJTHEMGYRE600222EGTXTKNO6005130030906036761666300485300584688373HNSA603207.SSRevenue growth (TTM) →EV / Sales →
Further right = faster growth; higher = more expensive. The dashed lines are the peer medians. Shanghai Xiao Fang Pharmaceutical is the large dot.

Capital: growth delivered against growth the price implies

0%+50%+100%0%50%100%600222AARTIDRUGS6036760021071666301277HNSA603207.SSGrowth delivered (Del g) →Growth the price implies (Req g, 7 yrs) →
Above the diagonal = the price needs more growth than the company has been delivering; below = the price already allows for a slowdown. Shanghai Xiao Fang Pharmaceutical is the large dot.

Shanghai Xiao Fang Pharmaceutical competitors and peer comparison

How Shanghai Xiao Fang Pharmaceutical compares with its peers

Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.

Shanghai Xiao Fang Pharmaceutical against its 20 peers (data as of 18 Nov 2026)
Measure603207.SSPeer medianRank in peer set
1-month return-6.7%-2.1%9th lowest of 21
6-month return-17.3%-19.6%10th highest of 21
Distance from 52-week high-35.8%-37.1%11th highest of 21
Revenue growth (TTM)+9.8%+9.4%10th highest of 20
Operating margin39.4%6.8%highest of 20
EV / Sales4.8×3.7×8th most expensive of 20
Growth the price implies (Req g, 7 yrs)-5.4%4.6%3rd least demanding of 9
Growth delivered (Del g)+7.6%+5.3%4th highest of 9
Hurdle (Req g minus delivered)-13.0 pp+2.1 pp4th least demanding of 9
ROIC minus cost of capital+34.7 pp-2.7 pphighest of 18

Peer table

Peer set: Industry: the same industry and sector in any market, nearest in size
CompanyMarketMarket cap6M returnRevenue growthOp. marginEV / SalesReq gDelivered g
Shanghai Xiao Fang Pharmaceutical 603207.SSChina$503M-17%+10%39%4.8×-5.4%+7.6%
Gujarat Themis Biosyn GUJTHEM.NSIndia$505M+2%+18%39%27.2×n/an/a
Gyre Therapeutics GYREUnited States$500M-28%+14%-18%4.0×n/an/a
Indaptus Therapeutics INDPUnited States$505M+147%n/an/an/an/an/a
Henan Taloph Pharmaceutical Stock 600222.SSChina$497M-21%-5%7%2.5×16.7%+4.4%
Egetis Therapeutics EGTX.STSweden$509M+76%+27%-645%71.0×n/an/a
Alpha Teknova TKNOUnited States$496M+113%+15%-32%11.0×n/an/a
Jiangsu Lianhuan Pharmaceutical 600513.SSChina$496M-41%+14%0%1.8×n/an/a
Daewoong 003090.KSSouth Korea$495M-28%+6%11%0.9×n/an/a
Aarti Drugs AARTIDRUGS.NSIndia$494M+34%+15%11%1.8×22.1%+3.5%
Xizang Weixinkang Pharmaceutical 603676.SSChina$513M-22%-8%16%2.3×-6.1%+9.6%
Shandong Wohua Pharmaceutical 002107.SZChina$493M-20%-4%18%3.7×5.9%-4.1%
Tong Ren Tang Technologies 1666.HKHong Kong$491M-19%-14%12%0.6×-17.2%+6.3%
Beijing Science Sun Pharmaceutical 300485.SZChina$517M-29%-11%-8%5.6×n/an/a
Newland Pharmaceutical 301277.SZChina$488M-22%+9%11%3.5×8.9%+9.1%
Nanjing Hicin Pharmaceutical 300584.SZChina$487M-29%+32%17%4.3×3.3%-1.1%
Hefei Lifeon Pharmaceutical 003020.SZChina$486M-21%-1%10%2.0×n/an/a
Shanghai MicuRx Pharmaceutical 688373.SSChina$481M-8%+23%-61%19.0×n/an/a
REGENXBIO RGNXUnited States$480M+22%-5%-120%3.1×n/an/a
Hansa Biopharma HNSA.STSweden$479M+39%+69%-190%14.9×-4.7%+105.3%
Shanghai Fudan Forward S&T 600624.SSChina$478M0%-14%-34%6.4×n/an/a

Questions

Which companies are Shanghai Xiao Fang Pharmaceutical's closest peers?
The cockpit's peer set: Gujarat Themis Biosyn (GUJTHEM.NS), Gyre Therapeutics (GYRE), Indaptus Therapeutics (INDP), Henan Taloph Pharmaceutical Stock (600222.SS), Egetis Therapeutics (EGTX.ST), Alpha Teknova (TKNO), Jiangsu Lianhuan Pharmaceutical (600513.SS), Daewoong (003090.KS).
Is Shanghai Xiao Fang Pharmaceutical expensive compared with its peers?
On ev / sales it trades at 4.8× against a peer median of 3.7×, 8th most expensive of 20 in its peer set. For today's price to make sense, revenue must grow about -5% a year for seven years (Req g). Recent delivered growth is +8%, so the hurdle is -13 pp: the price already allows for a slowdown.
How has Shanghai Xiao Fang Pharmaceutical stock performed?
Over six months to 18 Nov 2026 the shares returned -17.3% against -19.6% for the median peer; over one year -35.1%.

How these numbers are made. Returns are close-to-close in local currency. Revenue growth and margins are trailing twelve months. Req g is the revenue growth that today's enterprise value requires for seven years at the company's own cost of capital; Delivered g is what it actually grew; the gap is the hurdle (honest precision about ±8 points, so read the ranking more than the decimal). No fair values, price targets or analyst ratings are shown, by design. Method and validation.